Selpercatinib to treat RET-driven lung & thyroid cancersJune 10, 2020
Eli Lilly said the US FDA has approved selpercatinib (Retevmo), 40 mg & 80 mg capsules, the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
The drug is also indicated for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
The drug was approved under the FDA’s Accelerated Approval regulations based on the LIBRETTO-001 phase 1/2 trial’s endpoints of objective response rate (ORR) and duration of response (DoR).
Selpercatinib is a selective RET kinase inhibitor. It may affect both tumour cells and healthy cells, which can result in side effects.
It is taken twice daily until disease progression or unacceptable toxicity.